Table 3.
Cox proportional hazards models for overall survival
| Characteristics | Univariate analyses | Multivariable model | |||
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | ≥65 vs <65 | – | 0.97 | – | – |
| Gender | Female vs male | – | 0.81 | – | – |
| Smoking | Current vs never/former | – | 0.93 | – | – |
| ECOG PS | 2 vs 0–1 | 3.60 (1.70 to 7.60) | <0.001 | 2.24 (1.01 to 4.95) | 0.04 |
| Histology | Non-squamous vs squamous | – | 0.13 | – | – |
| PD-L1 status | Positive vs negative | – | 0.20 | – | – |
| Metastatic sites (N) | >2 vs 1–2 | – | 0.22 | – | – |
| Brain mets | Yes vs no | – | 0.37 | ||
| Liver mets | Yes vs no | – | 0.05 | ||
| Bone mets | Yes vs no | – | 0.03 | – | 0.09 |
| Line of treatment | >2 vs 1–2 | – | 0.85 | – | – |
| ICI regimen | Dual vs mono | – | 0.93 | – | – |
| Early use of steroids | Yes vs no | 2.60 (1.70 to 4.10) | <0.001 | 2.38 (1.48 to 3.83) | <0.001 |
P values below the significance threshold are reported in bold.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor.